Belantamab mafodotin, Venetoclax

Antibody–drug conjugate

Belantamab mafodotin, Venetoclax is one of 24 small molecule programs targeting Multiple Myeloma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaActive, not recruiting

Multiple MyelomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

Prolia

Amgen

Preclinical

5 3

Eliquis

Bristol-Myers Squibb

Preclinical

3 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 5

Adriamycin

GGynecologic Oncology Group

Preclinical

9 6

Nolvadex

AstraZeneca

Preclinical

1 7

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 8

Intron a

Systemic Therapy

1 10

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Multiple Myeloma

NCT05853965

Clinical

Trials by Indication[1]

Multiple Myeloma1 trial

Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory T(11;14) Multiple Myeloma

Recruiting·UUniversitätsklinikum Hamburg-Eppendorf·Phase 1/2·NCT05853965·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Belantamab mafodotin, Venetoclax. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Belantamab mafodotin, Venetoclax compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Belantamab mafodotin, Venetoclax. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universitätsklinikum Hamburg-Eppendorf company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate[2]
Company: UUniversitätsklinikum Hamburg-Eppendorf

Belantamab mafodotin, Venetoclax

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News